4d Molecular Therapeutics Inc (FDMT) - News Archive

Transformative Advances in Cystic Fibrosis Treatment: 4D Molecular Therapeutics and the Future of 4D-710 Cystic fibrosis (CF) is a life-threatening genetic disorder that primarily affects the lungs, leading to severe re...

4D Molecular Therapeutics Expands Workforce and Financial Footprint Amid Renewed Investment Opportunities EMERYVILLE, Calif. April 11, 2025 - In a significant advancement for 4D Molecular Therapeutics (Nasdaq: FDMT), a...

Emeryville, Calif. August 27, 2024 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading clinical-stage genetic medicines company, has announced its plans to host a 4D-150 Wet AMD Development Day on...

4DMT Expands Leadership and Vision in Ophthalmology Amid Significant Revenue Growth Emeryville, Calif. August 5, 2024 4D Molecular Therapeutics (Nasdaq: FDMT), a frontrunner in the realm of genetic medicines, has made s...

4D Molecular Therapeutics: Advancements, Challenges, and Promising ResultsIn the realm of drug discovery and gene therapy, 4D Molecular Therapeutics (FDMT) has emerged as a key player, continuously pushing the boundarie...

4D Molecular Therapeutics: Trailblazing Genetic Medicines for Wet AMD and Cystic Fibrosis By Author NameEMERYVILLE, Calif. In what can only be described as a groundbreaking year, 4D Molecular Therapeutics (Nasdaq: FDMT,...

At this year s Clinical Trials at the Summit 2024 in Park City, Utah, the spotlight was on 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company. 4DMT presente...

A Promising Leap Forward in Cystic Fibrosis Treatment: Interim Data from 4DMT s AEROW Clinical Trial Cystic fibrosis (CF) is a debilitating genetic disorder that severely impacts lung function. Traditional therapeutic s...

In recent years, significant progress has been made in the field of genetic medicines, opening up new possibilities for the treatment of large market diseases. 4D Molecular Therapeutics (4DMT), a clinical-stage genetic...

4D Molecular Therapeutics (4DMT), a renowned genetic medicines company, has recently shared exciting news about the interim data from its Phase 1/2 AEROW clinical trial for aerosolized 4D-710, a potential breakthrough t...

In recent years, genetic medicine has emerged as a groundbreaking field in the fight against numerous diseases. Among these diseases, Cystic Fibrosis (CF) has posed significant challenges due to its complex genetic natu...

4D Molecular Therapeutics (4DMT), a pioneering clinical-stage genetic medicines company, shared updated interim safety and efficacy data on their investigational therapy, 4D-310, for the treatment of Fabry disease cardi...

4D Molecular Therapeutics Raises Approximately $300 Million in Upsized Public OfferingEMERYVILLE, Calif., Feb. 06, 2024 - 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage genetic medicines company, has s...

As the globe continues to battle a range of diseases, advancements made in the field of genetic medicines have been critical in altering the course of disease management. In cognizance of this, 4D Molecular Therapeutics...

In an outstanding demonstration of biotech synergy, 4D Molecular Therapeutics(Nasdaq: FDMT, 4DMT), a trailblazing clinical-stage genetic medicines enterprise, and Arbor Biotechnologies, Inc., an innovative gene editing...

4D Molecular Therapeutics (4DMT), a renowned clinical-stage genetic medicines company, has recently announced that its investigational genetic medicine candidate, 4D-150, has received the Regenerative Medicine Advanced...